Editorial Note: This article is written with editorial review and topic relevance in mind.
Exelixis completed its last restructuring in january 2024, saying goodbye to 175 staffers in another effort to consolidate focus on label expansions for cabometyx and the development of. As a diverse, growing team, everyone at exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts. Sector, cabozantinib growth, zanzalintinib upside, and fda/q4 catalysts.
The Dubuque Advertiser October 12, 2022 by The Dubuque Advertiser Issuu
It operates as a developer of small molecule drugs for the treatment of cancer. Exelixis is a public company based in san francisco (united states), founded in 1994. Find out how we're dedicated to giving more patients hope for the future.
Get to know the exelixis pipeline and see an overview of our molecules along with their moa.
Food and drug administration (fda) for.
